Red Rock Resorts earnings beat by $0.54, revenue topped estimates
Investing.com -- Shares of Laboratorios Farmaceuticos ROVI SA (BME:ROVI) climbed 3.5% as the company outlined an ambitious medium-term (MT) guidance for the year 2030, suggesting significant growth in operating revenue and EBITDA.
ROVI’s forecast includes a projection of operating revenue reaching 1.5x to 1.8x the 2024 level of €763.7 million, which translates to a guidance range of €1,146 million to €1,375 million. The company expects its Contract Development and Manufacturing Organization (CDMO) revenue to hit approximately €700 million by 2030, accounting for 51% to 61% of the group’s operating revenues.
Despite anticipating "low single digit" growth for its Sx Pharma Revenue compared to 2024, ROVI projects a substantial increase in EBITDA pre-R&D, targeting 2.5x to 2.8x the FY24 figure of €233.2 million, indicating a range of €583 million to €653 million. Margins are expected to remain robust, with EBITDA post-R&D margins forecasted between 43% and 47.4%, after accounting for average R&D expenses of €40 million to €60 million per year from 2025 to 2030.
Analysts at Jefferies commented on the guidance, noting, "We note the midpoint of Operating Revenue guidance gives a FY24-FY30E sales Compound Annual Growth Rate (CAGR) of 8.6% versus the company FY21-24 6% sales CAGR, driven by the expansion of the CDMO business.
The company plans for new CDMO contracts from 2026 onwards to drive growth and portfolio diversification. ROVI did disclose the signing of a new contract is time-consuming as expected, with 12-18 months from signature to commercial production, hence we expect the guidance to be back end loaded."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.